Accession Therapeutics Limited
David Krige has extensive work experience in the biotechnology and pharmaceutical industry. David is currently the Head of Translational Sciences at Accession Therapeutics Limited, a position they started in October 2022. Prior to their current role, David served as the Vice President of Translational Medicine at PsiOxus Therapeutics Ltd from September 2019 to October 2022. Before that, they were the Director of Translational Medicine at the same company from May 2018 to September 2019. From June 2014 to May 2018, David worked as the Head of Biomarkers at Immunocore. David also held the position of Head of Drug Discovery in the Science Funding Department at Cancer Research UK from October 2012 to June 2014. Earlier in their career, David served as a Group/Project Leader in Biology at Chroma Therapeutics from 2004 to 2012. David was also a Team Leader in Gene Discovery at Oxford BioMedica from 2000 to 2003. Prior to that, David worked as a Senior Scientist at British Biotech from 1994 to 2000. David obtained their PhD from the Royal Free Hospital, University of London, where they studied from 1990 to 1994. Overall, David Krige's work experience demonstrates their expertise in translational medicine, biomarkers, drug discovery, and gene discovery.
David Krige earned their BSc in Genetics from Queen Mary University of London in 1988. David then pursued an MSc in Applied Molecular Biology and Biotechnology with distinction at UCL from 1988 to 1989. Krige furthered their education and obtained a PhD in Biochemistry from the Royal Free Hospital, University of London, completing their studies in 1994.
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.